Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958334 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
A Phase 2 study of Uterine Fibroids, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 11
- Study locations
NCT00958334 is a Phase 2 study of Uterine Fibroids that has completed, run by Repros Therapeutics. The registered enrollment target is 65 participants, below the 238-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (73% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT00958334, a Phase 2 study of Uterine Fibroids, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 11
- Study locations
Study Summary
ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.
Conditions Studied
Interventions
- DRUG Proellex®
Study Locations (11)
Arizona
- Women's Health Research - Phoenix
- Arizona Wellness Centre for Women - Phoenix
California
- Medical Centre for Clinical Research - San Diego
- Women's Health Care, Inc. - San Diego
Texas
- Advances in Health Inc. - Houston
- Obstetrical & Gynecolgical Associates, PA (OGA) - Houston
Colorado
- Downtown Women's Health Care - Denver
Florida
- Insignia Clinical Research (Tampa Bay Women's Center) - Tampa
Nevada
- Affiliated Clinical Research, Inc. - Las Vegas
South Carolina
- SC Clinical Research Center - Columbia
Washington
- Women's Clinical Research Centre - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-09-07 |
| Est. Completion | 2008-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958334
The ClinicalTrials.gov registry entry for NCT00958334 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 10 other Uterine Fibroids trials with a reported enrollment target (73% lower). The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uterine Fibroids appearing as the primary indexed condition, and to 1 intervention - of which Proellex® is the first listed.
NCT00958334 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Arizona, California, Texas.
Frequently Asked Questions
What is clinical trial NCT00958334 about?
NCT00958334 is a clinical study titled "Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003". ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.
What is the current status of trial NCT00958334?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2006-09-07. Estimated completion is 2008-10-15.
What conditions does trial NCT00958334 study?
This clinical trial studies the following conditions: Uterine Fibroids.
What interventions are being tested in trial NCT00958334?
The interventions under investigation include: Proellex® (DRUG).
Who is sponsoring clinical trial NCT00958334?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00958334 being conducted?
This trial has 11 study locations across Arizona, California, Colorado, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Fibroids
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
COMPLETED · Phase 2
-
An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms
RECRUITING · NA
-
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
RECRUITING · Phase 3
-
Effect of Addition of Steroids on Duration of Analgesia
ACTIVE NOT RECRUITING · Early Phase 1
-
Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry
ACTIVE NOT RECRUITING
-
Uterine Leiomyoma Treatment With Radiofrequency Ablation
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.